Subscribe

4basebio PLC (88Q.F)

EUR5.50 +0.00 (+0.00%)
GB FSX Healthcare Biotechnology
Address 25 Norman Way CB24 5QE
Cambridge, GB
CEO Amy Jo Walker
Website 4basebio.com
IPO 2021-03-11
ISIN GB00BMCLYF79

Explore sections of this company profile

Also trades on Deutsche Börse · 88Q.DE (EUR) Frankfurt Stock Exchange · 88Q.F (EUR) London Stock Exchange · 4BB.L (GBp)
Description

4basebio PLC and its affiliated entities are dedicated to the research, development, production, and commercialization of synthetic DNA and RNA compounds, in addition to non-viral vector technologies. Their operations span across Europe, the United States, and other global markets. The company's innovative product portfolio includes: hpDNA: A unique double-stranded linear DNA featuring covalently closed hairpin structures at its ends, suitable for diverse viral and non-viral vector uses. opDNA: This partially opened, linear, double-stranded DNA is specifically engineered for in vitro transcription processes, enabling the generation of mRNA for vaccines and therapeutic applications. oeDNA (open-ended DNA): A linear, double-stranded DNA product optimally suited for advanced genome editing techniques. osDNA (open stabilized DNA): This product integrates specific nucleotide modifications within its DNA backbone, allowing for the precise modulation of its immunostimulatory properties, which is crucial for DNA vaccine development. The Hermes: A proprietary delivery system for nucleic acids and protein payloads, renowned for offering a thermo-stable alternative to conventional lipid-based delivery platforms. Established in 2008 and headquartered in Cambridge, United Kingdom, 4basebio PLC was formerly known as 4basebio UK Societas, adopting its current name in July 2021.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR5.50 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
91
Beta
0.90
Float Shares
5.70M
Free Float %
36.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+22.95% +32.74% +31.58% +22.95% -10.18% +9.49% -42.31% +16.28% +81.16% +130.77% +130.77%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
5.50
Quality scores
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +81.5% ★ Q4'25: +93.4% (vs Q4'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    -16.0% Q4'25: -75.8% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -1,058.4% Q4'25: -1,398.5% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -987.4% Q4'25: -1,637.0% (vs Q4'23)
  • ✗
    ROIC Biotechnology: -16.1%
    -185.1% Q4'25: -365.3% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +18.3% Q4'25: +26.1% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -1.07× Q4'25: -0.53× (vs Q4'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.87) × ERP
WACC = 85% × Ke + 15% × Kd (4.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 5.50
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
933.0K
est: 1.33M (-29.8%)
1.69M
est: 1.95M (-13.2%)
3.25M
3.02M – 3.48M
+66.6% YoY
13.92M
13.73M – 14.11M
+328.6% YoY
29.00M
28.61M – 29.39M
+108.3% YoY
40.60M
40.05M – 41.15M
+40.0% YoY
52.20M
51.50M – 52.91M
+28.6% YoY
EBITDA
-10.97M
est: -1.26M (-768.7%)
-15.57M
est: -1.85M (-740.8%)
-3.09M
-3.31M – -2.86M
-66.6% YoY
-13.22M
-13.40M – -13.04M
-328.6% YoY
-27.55M
-27.92M – -27.17M
-108.3% YoY
-38.56M
-39.09M – -38.04M
-40.0% YoY
-49.58M
-50.25M – -48.91M
-28.6% YoY
EBIT
-11.90M
est: -1.33M (-795.3%)
-16.72M
est: -1.95M (-757.3%)
-3.25M
-3.48M – -3.02M
-66.6% YoY
-13.92M
-14.11M – -13.73M
-328.6% YoY
-29.00M
-29.39M – -28.61M
-108.3% YoY
-40.60M
-41.15M – -40.05M
-40.0% YoY
-52.20M
-52.91M – -51.50M
-28.6% YoY
Net Income
-12.33M
est: -13.80M (+10.6%)
-16.91M
est: -16.55M (-2.1%)
-15.22M
-15.48M – -14.95M
+8.1% YoY
-9.13M
-9.29M – -8.97M
+40.0% YoY
-3.04M
-3.10M – -2.99M
+66.7% YoY
3.04M
2.99M – 3.10M
+200.0% YoY
7.61M
7.47M – 7.74M
+150.0% YoY
SGA
1.77M
est: 3.44M (-48.7%)
2.25M
est: 5.05M (-55.4%)
8.41M
7.81M – 9.02M
+66.6% YoY
36.06M
35.57M – 36.55M
+328.6% YoY
75.13M
74.11M – 76.14M
+108.3% YoY
105.18M
103.76M – 106.60M
+40.0% YoY
135.23M
133.40M – 137.06M
+28.6% YoY
EPS
-0.94
est: -1.05 (+10.7%)
-1.09
est: -1.26 (+13.6%)
-1.16
-1.18 – -1.14
+8.1% YoY
-0.70
-0.71 – -0.68
+40.0% YoY
-0.23
-0.24 – -0.23
+66.7% YoY
0.23
0.23 – 0.24
+200.0% YoY
0.58
0.57 – 0.59
+150.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-26 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-25 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
Ownership data is not available for this company yet.

Executive team

Top executives
EBIT / Employee
-1.5K
Shares Outstanding
15.48M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Amy Walker CEO & Director 355.7K —
Christine Wolosin Chief Commercial Officer — female
Jennifer Gelman Vice President of Marketing — female
Manja Hermina Elisabeth Maria Boerman Executive Chair of the Board — —
Scott Lorimer Chief Operating Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology